December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Oral AZA (CC-486) significantly improved OS and RFS in patients with CR/CRi AML regardless of baseline MRD status, although baseline MRD positivity showed reduced benefit.